Research & Education

Combined Treatment - Stage III NSCLC

Monday, July 20, 2015 - 8 p.m. EDT - Recording Available

 

 Suresh Senan, MD, PhD, FRCR  

Suresh Senan, MD, PhD, FRCR
Department of Radiation Oncology
VU University Medical Center in
Amsterdam, The Netherlands

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

 

Name of Planner(s): 

 

      Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Combined Treatment - Stage III NSCLC

Date of Activity:

 

07/20/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

Suresh Senan, MD, PhD, FRCR- Speaker-

Member of trial management committee for proclaim trial sponsored by Eli Lilly

Speakers honoraria from Varian Medical Systems

Research agreement with Varian Medical Systems

RESOLUTION Of COI:

Ensure the activity includes a balanced discussion of alternative therapies.

Ramaswamy Govindan, MD –Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board.

 

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

        Yes     

If yes, please list: Unrestricted grant from: Celgene, Genentech and Bristol-Meyers Squibb

IASLC continues the Lung Cancer Grand Round Series in 2015 with this LIVE WEBINAR featuring Professor Suresh Senan.

The outcomes of concurrent chemo-radiotherapy from two phase III randomized trials, which together enrolled more than 1,100 patients, have recently been reported. Similarly, data from recent trials comparing chemo-radiotherapy with trimodality approaches (incorporating surgery) are now available. With these results, the focus is now geared towards investigational approaches that merit evaluation in future clinical trials. The implications of these results on current treatment and future clinical trials is the subject of this session of the 2015 Lung Cancer Grand Rounds series.

After attending this session, participants will be able to:

  1. Illustrate results of recent phase III trials in the context of current treatment guidelines (with a focus on radiotherapy dose and choice of chemotherapy regimen)
  2. Apply patient selection criteria for specific therapeutic approaches
  3. Define anticipate toxicities associated with the current generation of chemo-radiotherapy regimens

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

The outcomes of concurrent chemo-radiotherapy from two phase III randomized trials, which together enrolled more than 1,100 patients, have recently been reported. Similarly, data from recent trials comparing chemo-radiotherapy with trimodality approaches (incorporating surgery) are now available. With these results, the focus is now geared towards investigational approaches that merit evaluation in future clinical trials. The implications of these results on current treatment and future clinical trials is the subject of this session of the 2015 Lung Cancer Grand Rounds series.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

DOWNLOAD RECORDING 

 

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Agreement

IASLC Commercial Support Letter of Agreement (LOA)

 

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2015. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

 

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Monday, July 20, 2015 at 8:00:00 PM EDT UTC-4 hours
Denver (U.S.A. - Colorado) Monday, July 20, 2015 at 6:00:00 PM MDT UTC-6 hours
London (United Kingdom - England) Tuesday, July 21, 2015 at 1:00:00 AM BST UTC+1 hour
Rome (Italy) Tuesday, July 21, 2015 at 2:00:00 AM CEST UTC+2 hours
New Delhi (India - Delhi) Tuesday, July 21, 2015 at 5:30:00 AM IST UTC+5:30 hours
Moscow (Russia) Tuesday, July 21, 2015 at 3:00:00 AM MSK UTC+3 hours
Shanghai (China - Shanghai Municipality) Tuesday, July 21, 2015 at 8:00:00 AM CST UTC+8 hours
Sydney (Australia - New South Wales) Tuesday, July 21, 2015 at 10:00:00 AM AEST UTC+10 hours
Tokyo (Japan) Tuesday, July 21, 2015 at 9:00:00 AM JST UTC+9 hours
Corresponding UTC (GMT) Tuesday, July 21, 2015 at 12:00:00 AM     

How to use the Time Zone Converter

This series is supported in part by unrestricted educational grants provided by Bristol-Myers Squibb Co., Celgene and Genentech